STOCK TITAN

Zivo Bioscience Inc - ZIVO STOCK NEWS

Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.

Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a biotechnology innovator focused on developing natural bioactive compounds derived from proprietary algal strains. This page serves as the definitive source for all official company announcements, research milestones, and strategic developments.

Investors and industry stakeholders will find timely updates including financial results, partnership agreements, regulatory filings, and scientific advancements. Our curated news feed provides essential insights into ZIVO's progress in nutraceutical research and biotech applications.

The page organizes content by key categories: quarterly earnings disclosures, product development breakthroughs, intellectual property updates, and corporate governance matters. Each news item is presented with clear context to help users assess material developments.

Bookmark this resource for streamlined tracking of Zivo Bioscience's advancements in algal-based biotechnology. Check regularly for verified updates directly from company filings and authorized communications.

Rhea-AI Summary
Zivo Bioscience announces a 1-for-6 reverse stock split to regain compliance with Nasdaq listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Summary
Zivo Bioscience, Inc. announces participation in the 8th Annual Dawson James Small Cap Growth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.94%
Tags
conferences
-
Rhea-AI Summary
ZIVO Bioscience announces positive results from coccidiosis trial in broiler chickens, demonstrating statistically significant improvements in broiler health. The product candidate showed potential to mitigate the effects of coccidiosis through a non-antibiotic mechanism of action. ZIVO plans to launch the final phase of validation with results expected by the end of 2023. The company remains confident in the stability and effectiveness of its product candidate, presenting a disruptive solution to coccidiosis in the poultry industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
Rhea-AI Summary
Zivo Bioscience, Inc. announces that ZWorldwide, its exclusive distributor in North America, will purchase the entire supply of Zivolife for the first 18 months. ZWorldwide has also committed to purchasing at least 24,000 kilograms of product for each of the next five years. ZIVO is collaborating with Alimenta Algae to increase production volumes and expects a new facility to be fully operational in 2025, capable of producing up to 100,000 kilograms of dried product per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Summary
Zivo Bioscience announces commercialization of proprietary algal biomass as food ingredient. Signs distribution agreement with ZWorldwide for branded DTC sales of ZivolifeTM. Also signs manufacturing agreement with Alimenta Algae to grow and process algal biomass. ZivolifeTM is the company's first revenue-generating product. Global food and beverage microalgae market projected to reach $247 million by 2033. ZivolifeTM is natural, non-GMO, and a source of plant-based protein, beta glucan, and fiber.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.09%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary

Zivo Bioscience, Inc. (NASDAQ: ZIVO) announced a $1 million unsecured loan from its CEO, John Payne, to support working capital and a validation study for its coccidiosis treatment for broiler chickens. The loan has a 10% interest rate and includes warrants for 390,000 shares at $2.91 each. The company aims to validate its immune-modulating product, with results expected by mid-2023. Payne expressed confidence in Zivo's team and strategies, while CFO Keith Marchiando emphasized the significance of this support for funding beyond the current study. Zivo also continues to scale up production for the human food industry, showcasing its commitment to both animal and human health avenues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Zivo Bioscience (NASDAQ: ZIVO) announced disappointing results from a recent study on a novel immune-modulating product for coccidiosis treatment in broiler chickens, conducted by a third party. The trial faced a significantly higher than usual mortality rate due to an intense disease challenge, yielding results not reflective of commercial production conditions. Despite this setback, ZIVO remains confident in its product's potential and plans to conduct a new study, expected to conclude by mid-year. The company continues to prioritize coccidiosis treatment while exploring additional health benefits from its proprietary algal cultures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.1%
Tags
none
Rhea-AI Summary

Zivo Bioscience has announced the formation of a wholly-owned subsidiary, ZIVOLife, which will hold an exclusive worldwide limited license to utilize the company's intellectual property for producing and supplying whole biomass algal products. This strategic move aims to enhance its corporate structure, capitalize on agtech market opportunities, and expedite revenue generation. Upon finalizing a license agreement, Zivo is set to receive royalty payments from ZIVOLife. A conference call is planned for early November to discuss these developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
none
Zivo Bioscience Inc

Nasdaq:ZIVO

ZIVO Rankings

ZIVO Stock Data

66.54M
1.86M
50.32%
0.07%
2.04%
Biotechnology
Healthcare
Link
United States
Bloomfield Hills